-
Mashup Score: 0
Find original research, groundbreaking studies, peer-reviewed academic literature, and publish your own manuscript on Value-Based Cancer Care.
Source: www.valuebasedcancer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Serious Illness Care Research: Exploring Current Knowledge, Emerging Evidence and Future Directions: A Workshop - 1 year(s) ago
Register for this event from the National Academies of Sciences, Engineering, and Medicine.
Source: events.nationalacademies.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Join @NASEM_Health’s Roundtable on Quality Care for People with Serious Illness for a workshop exploring the current knowledge, emerging evidence, and the future directions of serious illness care research. Register here: https://t.co/YVCApKzfFs #SeriousIllnessCareNASEM
-
-
Mashup Score: 0The Future of AI in Cancer Care - The ASCO Post - 1 year(s) ago
New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Researchers have long investigated the potential of AI to transform cancer care and improve patient outcomes. According to Amara’s Law, individuals tend to overestimate the short-term impacts of technology but underestimate its long-term effects. However, caution may be
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
➡️Future of AI in cancer care @ASCOPost article linking ESMO GROW (#RWD reporting standards) with #AI applied to #oncology and the new @myESMO RWD and Digital Oncology Journal @OncologyAdvance https://t.co/3b1VrgQxVb https://t.co/oKksEd8wyR
-
-
Mashup Score: 0Bias Reporting in the Clinical Learning Environment: A National Survey of Internal Medicine Clerkship Directors - PubMed - 1 year(s) ago
Bias reports remain heterogeneous, are likely underreported, and lack best practice responses. There is a need to systematically capture bias events to work toward a just culture that fosters accountability and to identify bias events through more robust reporting.
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful manuscript from our stellar educational leadership @URMC_DeptMed @UR_HMD @amyblattMD Bias Reporting in the Clinical Learning Environment: A National Survey of Internal Medicine Clerkship Directors https://t.co/yTou5xkZAG
-
-
Mashup Score: 0International Lung Cancer Survivorship Conference - 1 year(s) ago
The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The conference provides opportunities for attendees to hear from world-renowned researchers on the latest treatments, learn about ways to man…
Source: reg.eventmobi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
.@CharlesSwanton was also our keynote speaker for @LUNGevity's #ILCSC23 and did a phenomenal job on this topic! Everyone can view his talk by registering for free here: https://t.co/tha2bpruei All sessions will be available through Dec 21, 2023! https://t.co/JWRCz428xs
-
-
Mashup Score: 18How to see peak foliage in the Adirondacks—without the crowds - 1 year(s) ago
The most popular trails in this New York State park are showing signs of ecological distress—but there are plenty of quieter, less trafficked regions worth exploring.
Source: www.nationalgeographic.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @NatGeo: Here's how to see peak foliage in the Adirondacks—without the crowds https://t.co/4H35is6Joa
-
-
Mashup Score: 0Letter to the Editor: The Dark Side of CAR-T | ASH Clinical News | American Society of Hematology - 1 year(s) ago
In her May 2023 Editor’s Corner, Brea Lipe, MD, discussed the dark side of chime ric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Given their high and durable response rates, there has been much excitement around the use of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), though various challenges have hindered widespread implementation of these therapies. Here, a reader continues the conversation, raising questions about whether patients with MM should
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Ide-cel and cilta-cel, two CAR T-cell therapies, have shown high response rates in patients; however, as the treatment landscape for #CAR T-cell therapy continues to change, discussions on navigating barriers to their widespread implementation remain key. https://t.co/GXsPKX0iNo
-
-
Mashup Score: 1Class and the City - 1 year(s) ago
The FCA’s consultation on diversity and inclusion will be out of step if it fails to tackle this aspect of the barriers to success
Source: www.ft.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Class and the @cityoflondon : UK @TheFCA ’s consultation on diversity and inclusion will be out of step if it fails to tackle this aspect of the barriers to success https://t.co/1i4IYrlwg4 via @NickBent https://t.co/V1zppb8703
-
-
Mashup Score: 2The high cost of prescription drugs: causes and solutions - 1 year(s) ago
Blood Cancer Journal – The high cost of prescription drugs: causes and solutions
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@kaitsulliva For more on prescription drug costs and what other policy changes are needed check out my paper here. @BloodCancerJnl #MedTwitter https://t.co/OLjNeK0dMp
-
-
Mashup Score: 2
Your parents’ income and wealth is of ever-growing importance in determining your own position in the lifetime income distribution.
Source: ifs.org.ukCategories: Hem/Oncs, Latest HeadlinesTweet-
Your parents’ income and wealth is of ever-growing importance in determining your own position in the lifetime income distribution. https://t.co/y5x2dywlwi via @ifs & @David_Sturrock et al https://t.co/3SINEb0QwF
-
Enjoyed talking about digital health and its impact on cancer care delivery at AVBCC and taking in the other sessions from thought leaders. @VBCancerCare. https://t.co/lAYGAR3hyi https://t.co/ds580NexYk